By All Means

“We’re going to be helping hundreds of thousands of patients with our device and that’s probably more than a lifetime of patients I could see as a physician.” By the time Allisa Song started medical school at Mayo Clinic in 2018, she was already the founder of an active medical device startup company called Nanodropper. The idea came to her in 2017, when she happened to read an article titled: "Drug Companies Make Eyedrops Too Big, and You Pay for the Waste.” “It really felt like we were letting people down,” Song says. “We have these great medications that are vision saving, and we’re dangling it in front of people, saying that you have to pay this amount if you want to keep your vision.” The cost, the structure of benefits—it all felt “unfair,” Song says. But rather than go for the big industry-wide fix, she approached the wasted eye medicine problem with a harm reductionist mentality. “I was just trying to think about how can we develop a solution that we could put directly into the hands of patients.”